New study to evaluate polygenic risk scores in heart disease prevention.
- The study aims to evaluate the use of polygenic risk scores.
- It will focus on pharmacogenomics testing in heart disease prevention.
- Collaboration is between the VA and Allelica.
The U.S. Department of Veterans Affairs (VA) is partnering with Allelica to conduct a clinical study aimed at improving cardiovascular disease prevention. This initiative will explore the effectiveness of polygenic risk scores and pharmacogenomics testing in identifying individuals at heightened risk for heart disease. The potential insights from this research could help tailor prevention strategies and interventions in at-risk populations.
This study will assess how incorporating polygenic risk scores may enhance traditional risk assessment methods in predicting cardiovascular disease. By integrating pharmacogenomics—a field that studies how genes affect a person's response to drugs—the collaboration aims to provide a more comprehensive approach to heart disease prevention for veterans. Researchers will collect and analyze data to determine the impact of these genetic tools on patient outcomes.
Through this collaboration, the VA and Allelica hope to pave the way for more personalized healthcare strategies in cardiovascular disease management. Understanding the genetic factors influencing heart disease can lead to better risk stratification and potentially more effective preventative measures.
